Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Pohlmann · SciRah

Researcher profile · Semantic Scholar

P. Pohlmann

Share profile

P. Pohlmann — researcher profile on SciRah

h-index: 27
Works: 130
Citations: 3,534

Most-cited papers

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
R. Freedman, R. Gelman, C. Anders, M. Melisko +26 more
2019Journal of Clinical Oncology308 citations Open access
Semantic Scholar
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies
D. Wolf, C. Yau, J. Wulfkuhle, L. Brown-Swigart +29 more
2022Cancer Cell295 citations Open access
Semantic Scholar
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial
S. Adams, J. Diamond, E. Hamilton, P. Pohlmann +8 more
2019JAMA Oncology271 citations Open access
Semantic Scholar
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer
V. Jansen, Neil E. Bhola, J. Bauer, L. Formisano +15 more
2017Cancer Research207 citations Open access
Semantic Scholar
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).
S. Adams, J. Diamond, E. Hamilton, P. Pohlmann +6 more
2016127 citations
Semantic Scholar
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
S. Tolaney, N. Tayob, C. Dang, D. Yardley +43 more
2021Journal of Clinical Oncology111 citations
Semantic Scholar
Adjuvant platinum-based chemotherapy for early stage cervical cancer.
F. Falcetta, L. R. Medeiros, M. I. Edelweiss, P. Pohlmann +2 more
2016Cochrane Database of Systematic Reviews111 citations Open access
Semantic Scholar
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
M. Pishvaian, E. Blais, R. J. Bender, Shruti Rao +15 more
2019JAMIA Open82 citations Open access
Semantic Scholar
Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux
Brandon C. Jones, P. Pohlmann, Robert Clarke, S. Sengupta
2022Cancer Metastasis Review53 citations
Semantic Scholar
Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions
G. Onzi, N. D’Agustini, S. Garcia, S. S. Guterres +3 more
2022Drug Safety42 citations
Semantic Scholar
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J. Ruddy, Yue Zheng, N. Tayob, Jia-Ni Hu +41 more
2021Breast Cancer Research and Treatment36 citations
Semantic Scholar
Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis
Jerry Xiao, P. Pohlmann, C. Isaacs, B. Weinberg +3 more
2021Biomedicines34 citations Open access
Semantic Scholar
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
Katia Khoury, F. Lynce, A. Barac, X. Geng +14 more
2021Breast Cancer Research and Treatment33 citations Open access
Semantic Scholar
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
J. Boughey, Michael D. Alvarado, Rachael B. Lancaster, W. Symmans +46 more
2018npj Breast Cancer33 citations Open access
Semantic Scholar
Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
S. Adams, J. Diamond, E. Hamilton, P. Pohlmann +7 more
201631 citations
Semantic Scholar
Video intervention increases participation of black breast cancer patients in therapeutic trials
Brandi N. Robinson, Antoinette F. Newman, E. Tefera, P. Herbolsheimer +14 more
2017npj Breast Cancer29 citations Open access
Semantic Scholar
Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors
Akanksha Mahajan, Bruna M Sugita, A. Duttargi, Francisco R. Saenz +7 more
2017PLoS ONE29 citations Open access
Semantic Scholar
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
D. Yee, C. Isaacs, D. Wolf, C. Yau +51 more
2021npj Breast Cancer28 citations Open access
Semantic Scholar
O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies
S. Piha-Paul, J. Bendell, A. Tolcher, S. Hurvitz +14 more
2020Journal of Immunotherapy for Cancer28 citations Open access
Semantic Scholar
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway
A. Heeke, J. Xiu, A. Elliott, W. Korn +7 more
2020Breast Cancer Research and Treatment26 citations
Semantic Scholar
Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis
Jerry Xiao, J. McGill, K. Stanton, Joshua D Kassner +5 more
2020Cancers24 citations Open access
Semantic Scholar
Hematological Safety of Palbociclib in Combination With Endocrine Therapy in Patients with Benign Ethnic Neutropenia and Advanced Breast Cancer
F. Lynce, M. Blackburn, Rebecca Zhuo, C. Gallagher +12 more
2021Cancer18 citations Open access
Semantic Scholar
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer
Katia Khoury, A. Tan, A. Elliott, J. Xiu +9 more
2020Frontiers in Oncology18 citations Open access
Semantic Scholar
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens
Jennifer Gao, M. Tan, P. Pohlmann, S. Swain
2016Clinical Breast Cancer18 citations Open access
Semantic Scholar
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Y. Abdou, E. Dees, J. Mortimer, P. Pohlmann +14 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).
Katia Khoury, R. Feldman, P. Pohlmann, A. Heeke +7 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
E. Dumbrava, Manish R. Sharma, R. Carvajal, D. Catenacci +20 more
202115 citations
Semantic Scholar
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
R. Barroso-Sousa, P. Tarantino, N. Tayob, C. Dang +45 more
2022npj Breast Cancer14 citations Open access
Semantic Scholar
Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis
Jerry Xiao, U. Sharma, Abolfazl Arab, S. Miglani +14 more
2023Cancers13 citations Open access
Semantic Scholar
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
Yoshiaki Nakamura, N. Mizuno, Y. Sunakawa, E. Hamilton +15 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Molecular characterization of ESR1 variants in breast cancer
A. Heeke, A. Elliott, R. Feldman, H. O’Connor +12 more
2022Breast Cancer Research and Treatment12 citations Open access
Semantic Scholar
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
S. Hurvitz, E. Hamilton, A. Spira, P. Pohlmann +11 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
F. Lynce, M. Saleh, Ayesha N. Shajahan-Haq, C. Gallagher +8 more
2018Contemporary Clinical Trials Communications10 citations Open access
Semantic Scholar
Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer.
Bilal Elchaarani, Hillary Stires, P. Pohlmann, R. Riggins
201710 citations
Semantic Scholar
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.
Tina Roy, Elizabeth Barrows, C. Mainor, J. Collins +3 more
2023Contemporary Clinical Trials Communications9 citations Open access
Semantic Scholar
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
P. Pohlmann, D. Graham, Tianmin Wu, Y. Ottaviano +12 more
2022Breast Cancer Research and Treatment9 citations Open access
Semantic Scholar
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
Wendy Y. Chen, K. Ballman, E. Winer, T. Openshaw +11 more
2022Journal of Clinical Oncology9 citations
Semantic Scholar
An evaluation of palbociclib as a breast cancer treatment option: a current update
Gregory T. Gallanis, Ramon I Pericas, A. Riegel, P. Pohlmann
2020Expert Opinion on Pharmacotherapy9 citations Open access
Semantic Scholar
401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Manish R. Sharma, E. Dumbrava, R. Carvajal, D. Catenacci +20 more
2020Journal for ImmunoTherapy of Cancer9 citations Open access
Semantic Scholar
Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study
Katia Khoury, C. Isaacs, M. Gatti-Mays, R. Donahue +9 more
2019Ongoing Clinical Trials7 citations
Semantic Scholar
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
F. Lynce, M. Blackburn, Ling Cai, Heping Wang +4 more
2017Breast Cancer Research and Treatment7 citations Open access
Semantic Scholar
Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)
P. Tarantino, N. Tayob, C. Dang, D. Yardley +46 more
2023Cancer Research6 citations
Semantic Scholar
Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients
S. Telang, K. Yaddanapudi, J. Grewal, R. Redman +6 more
20166 citations
Semantic Scholar
Emerging Landscape of Targeted Therapy of Breast Cancers With Low HER2 Protein Expression.
G. Tozbikian, S. Krishnamurthy, M. Bui, Michael Feldman +6 more
2023Archives of Pathology & Laboratory Medicine5 citations Open access
Semantic Scholar
Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study
F. Lynce, C. Mainor, X. Geng, Greg Jones +24 more
2022Cancer Research5 citations
Semantic Scholar
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
A. Heeke, J. Xiu, F. Lynce, P. Pohlmann +5 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Abstract 907: Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers
S. Sengupta, Catherine M. Sevigny, Xiaoyi Liu, Lu Jin +2 more
2018Experimental and Molecular Therapeutics5 citations
Semantic Scholar
A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers.
S. Madhavan, E. Blais, R. J. Bender, V. Chung +13 more
20185 citations
Semantic Scholar
Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status
E. Hamilton, M. Reinisch, S. Loi, A. Okines +19 more
2021Poster Spotlight Session Abstracts4 citations
Semantic Scholar
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
F. Lynce, Hong-Kun Wang, E. Petricoin, P. Pohlmann +7 more
2019Cancer Chemotherapy and Pharmacology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Isaacs×16
Invite
C. Isaacs — researcher profile on SciRah
F. Lynce×16
Invite
F. Lynce — researcher profile on SciRah
S. Swain×10
Invite
S. Swain — researcher profile on SciRah
S. Tolaney×7
Invite
S. Tolaney — researcher profile on SciRah

×7

Invite

R. Nanda — researcher profile on SciRah

Invite

H. Rugo — researcher profile on SciRah

Invite

E. Hamilton — researcher profile on SciRah

Invite

K. Albain — researcher profile on SciRah

A. Forero-Torres×6

Invite

A. Forero-Torres — researcher profile on SciRah

C. Gallagher×6

Invite

C. Gallagher — researcher profile on SciRah

Invite

A. Dilawari — researcher profile on SciRah

Invite

A. Tan — researcher profile on SciRah